Search results for "COVID-19 vaccines"

showing 10 items of 55 documents

Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents

2022

6 páginas, 2 figuras, 3 tablas. Se puede acceder al texto completo de este artículo desde PubMedCentral: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490129 . Los datos de investigación utilizados en el mismo, se encuentran disponibles en: https://doi.org/10.1016/j.cmi.2021.09.031.

MaleMicrobiology (medical)medicine.medical_specialtyCOVID-19 VaccinesSARS-CoV-2-S antibodiesFingerstickSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Nursing home residentsCD8-Positive T-LymphocytesAntibodies ViralImmune systemComirnaty®COVID-19 vaccineInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overVenipuncturebiologybusiness.industrySARS-CoV-2COVID-19General MedicineNursing HomesVaccinationInfectious Diseasesbiology.proteinFemaleOriginal ArticleAntibodybusinessCD8
researchProduct

Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

2021

Abstract Introduction Although the COVID‐19 vaccination is deemed safe, exact incidence and nature if adverse effects, particularly dermatological ones, are still unknown. Objective To describe the demographic, clinical, morphological characteristics, outcomes, and timing of development of herpes zoster to the various COVID‐19 vaccines. And to identify on whether COVID‐19 vaccine has temporal relationship between development of herpes zoster (HZ). Methods We have performed a systemic review of articles from PubMed and Embase using MeSH and keywords like “Shingles,” “Herpes zoster,” “Varicella zoster,” “COVID‐19,” “Vaccine,” “SARS‐CoV‐2.” No filters including country of publication, language…

MalePediatricsmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)herpes zosterReview ArticleDermatologyMalignancyCovidVaricella zosterChickenpoxCOVID‐19vaccinemedicineHerpes Zoster VaccineHumansAdverse effectSARS-CoV-2business.industryIncidence (epidemiology)Metabolic disorderCOVID-19Middle Agedmedicine.diseaseVaccinationFemalebusinessShinglesJournal of Cosmetic Dermatology
researchProduct

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine.

2022

AbstractImmunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the pea…

MaleVaccinesSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaMultidisciplinaryCOVID-19 VaccinesSARS-CoV-2Immunoglobulin GCOVID-19HumansRNA ViralFemaleAntibodies ViralBNT162 VaccineScientific reports
researchProduct

The Dual/Global Value of SARS-CoV-2 Genome Surveillance on Migrants Arriving to Europe via the Mediterranean Routes.

2021

Despite the pandemic, 34,154 migrants, refugees or asylum-seekers landed in Sicily (Italy) in 2020, representing the main point of entry by sea into Europe. The SARS-CoV-2 surveillance program among migrants arriving to Sicily via the Mediterranean Sea, made by the combination of clinical examination and molecular testing, has been integrated by full-genome sequencing strains using the NGS technology from the last week of February. To date, more than one hundred full-genome strains have been sequenced and 8 different lineages have been identified mostly belonging to the lineages B.1.1.7 and B.1.525. As global access to COVID-19 vaccines should be ensured, the need to provide more detailed i…

Mediterranean climatePoint of entryCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RefugeeInfectious and parasitic diseasesRC109-216Genome ViralSettore MED/42 - Igiene Generale E ApplicataGenomeMediterranean seaPandemicHumansSocioeconomicsLetters to the EditorSicilyTransients and MigrantsSARS-CoV-2COVID-19General MedicineGeographyCOVID-19 COVID-19 Vaccines Genome Viral Humans Molecular Diagnostic Techniques SARS-CoV-2Sicily Transients and MigrantsMolecular Diagnostic TechniquesPublic aspects of medicineRA1-1270Annals of global health
researchProduct

N‐Terminal Modification of Gly‐His‐Tagged Proteins with Azidogluconolactone

2021

Site-specific protein modifications are vital for biopharmaceutical drug development. Gluconoylation is a non-enzymatic, post-translational modification of N-terminal HisTags. We report high-yield, site-selective in vitro α-aminoacylation of peptides, glycoproteins, antibodies, and virus-like particles (VLPs) with azidogluconolactone at pH 7.5 in 1 h. Conjugates slowly hydrolyse, but diol-masking with borate esters inhibits reversibility. In an example, we multimerise azidogluconoylated SARS-CoV-2 receptor-binding domain (RBD) onto VLPs via click-chemistry, to give a COVID-19 vaccine. Compared to yeast antigen, HEK-derived RBD was immunologically superior, likely due to observed diffe…

Models MolecularAzidesCOVID-19 VaccinesGlycosylationvirusesGlycineGluconatesBiochemistryLactoneschemistry.chemical_compoundAntigenHumansHistidineVaccines Virus-Like ParticleSeroconversionMolecular Biologychemistry.chemical_classificationMolecular StructurebiologyChemistryOrganic ChemistryAntibodies NeutralizingBiopharmaceuticalBiochemistrybiology.proteinClick chemistryMolecular MedicineAntibodyGlycoproteinConjugateChemBioChem
researchProduct

Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies

2021

AbstractThe availability of a COVID-19 vaccine has raised the issue of its compatibility with breastfeeding. Consequently, the Italian Society of Neonatology (SIN), the Italian Society of Pediatrics (SIP), the Italian Society of Perinatal Medicine (SIMP), the Italian Society of Obstetrics and Gynecology (SIGO), the Italian Association of Hospital Obstetricians-Gynecologists (AOGOI) and the Italian Society of Infectious and Tropical Diseases (SIMIT) have made an ad hoc consensus statement. Currently, knowledge regarding the administration of COVID-19 vaccine to the breastfeeding mother is limited. Nevertheless, as health benefits of breastfeeding are well demonstrated and since biological pl…

Position statementmedicine.medical_specialtyCOVID-19 VaccinesConsensusCoronavirus disease 2019 (COVID-19)BreastfeedingBreastfeedingConsensuHealth benefits03 medical and health sciences0302 clinical medicineObstetrics and gynaecology030225 pediatricsMedicalMedicineHumans030212 general & internal medicineVaccination.Societies Medicalbusiness.industryVaccinationlcsh:RJ1-570COVID-19lcsh:PediatricsBreastfeeding; COVID-19; Vaccination; COVID-19; Consensus; Female; Humans; Italy; Societies Medical; Breast Feeding; COVID-19 VaccinesSettore MED/38VaccinationBreast FeedingItalyFamily medicineCommentaryFemaleBiological plausibilitybusinessSocietiesBreast feedingHuman
researchProduct

Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization

2022

Abstract Aims Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has had a serious worldwide impact on human health. On December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting healthcare workers (HCWs). This study aims to investigate the antibodies that are response against SARS-CoV-2 vaccine. Methods and Results The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigated in 76 HCWs through a 4-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three diff…

Settore MED/07 - Microbiologia E Microbiologia ClinicaVaccines SyntheticCOVID-19 VaccinesSARS-CoV-2VaccinationCOVID-19General Medicineneutralizing antibodies.Settore MED/42 - Igiene Generale E ApplicataAntibodies ViralAntibodies NeutralizingApplied Microbiology and BiotechnologyKineticsItalyhealthcare workerImmunoglobulin GSpike Glycoprotein CoronavirusHumansmRNA Vaccineskinetics of antibodieBNT162 VaccineBiotechnologyJournal of Applied Microbiology
researchProduct

Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle…

2022

Background: This study aimed to investigate the early and longitudinal humoral response in Healthcare Workers (HCWs) after two doses of the BNT162b2 vaccine and to assess the association between metabolic and anthropometric parameters and the humoral response after vaccination. Methods: The study included 243 fully vaccinated HCWs: 25.50% previously infected with SARS-CoV-2 (with prior history of COVID-19—PH) and 74.40%—uninfected, seronegative before the first vaccination (with no prior history of COVID-19—NPH). IgG antibodies were measured, and sera were collected: prior to the vaccination, 21 days after the first dose, and 14 days and 8 months after the second dose. Res…

VaccinesCOVID-19 VaccinesSARS-CoV-2Health PersonnelMusclesCOVID-19Body Mass IndexInfectious DiseasesAdipose TissueMuscular DiseasesVirologyHumansIgG antibody; SARS-CoV-2; COVID-19; healthcare workers; health care professionals; COVID-19 vaccine; BNT162 vaccine; adipose tissue; body composition; immunizationRNA MessengerBNT162 VaccineViruses-Basel
researchProduct

Predicting COVID-19 booster vaccine intentions.

2022

Achieving broad immunity through vaccination is a cornerstone strategy for long-term management of COVID-19 infections, particularly the prevention of serious cases and hospitalizations. Evidence that vaccine-induced immunity wanes over time points to the need for COVID-19 booster vaccines, and maximum compliance is required to maintain population-level immunity. Little is known of the correlates of intentions to receive booster vaccines among previously vaccinated individuals. The present study applied an integrated model to examine effects of beliefs from multiple social cognition theories alongside sets of generalized, stable beliefs on individuals' booster vaccine intentions. US residen…

behavior changeand promotion of well-beingCOVID-19 VaccinesIntentionVaccine Relatedintegrated modelsClinical ResearchBehavioral and Social ScienceHumansPsychologyVaccinesPreventionrokotteetsosiaalinen kognitioVaccinationCOVID-19social cognition theoryPrevention of disease and conditionsrokotusGood Health and Well Being3.4 Vaccinesterveyskäyttäytyminenvaccine attitudes and beliefsvaccine hesitancyImmunizationrokotevastaisuus
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct